Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals is a recognized pharmaceutical company that uses state-of-the-art, cGMP-compliant facilities to develop, manufacture, and market biopharmaceutical injectable, intranasal, and inhalation products.

 

In addition to the Corporate Headquarters, Amphastar has five manufacturing facilities in the United States, China, and Europe, along with a state-of-the-art New Drug Research Center.

 

As a commitment to high quality, all Amphastar finished products are manufactured in the United States.

Metric
Company Name	Amphastar Pharmaceuticals, Inc.
Symbol	AMPH
MSH ID	COM:AMPHASTAR
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	US
Stage
Employee Count	1.76K
Website	amphastar.com
LinkedIn	amphastar-pharmaceuticals-inc.
Founders

Metric
Market Cap	1.83B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	644.39M
Revenue (LTM)
Revenue (NTM)
Gross Profit	343.97M
EBITDA	241.46M
Operating Income	199.69M
Net Income	137.54M
EPS	2.85
Diluted EPS	2.60
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.54
Operating Profit Margin	0.32
EBITDA Margin	0.37
Net Profit Margin	0.23
Return on Equity	0.25
Return on Assets	0.11
Return on Capital Employed	0.17

COM:AMPHASTAR

Amphastar Pharmaceuticals

Last Close

44.55

22/11 21:00

Market Cap

1.83B

Beta: -

Volume Today

394.77K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	18.88
P/B Ratio	4.29
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.47
EV Multiple	7.71

Metric
Days Sales Outstanding	73.14
Days Payables Outstanding	295.43
Days Inventory Outstanding	134.75
Operating Cycle	208.71
Cash Conversion Cycle	167.05
Asset Turnover	0.48

Metric
Operating Cash Flow	183.50M
Free Cash Flow	145.34M
Cash Flow to Debt	0.36
Operating Cash Flow/Sales	0.30
Free Cash Flow Yield	0.06

Metric
Cash & Equivalents	144.53M
Accounts Receivable	-26.09M
Inventory	105.83M
Goodwill	3.22M
Debt to Capitalization	0.48
Debt to Assets	0.44
Current Ratio	2.10
Quick Ratio	2.63

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03
R&D to Revenue	0.12
SG&A to Revenue	0.08